default author photo

Francesca L. Mordant

University of Melbourne - Department of Microbiology and Immunology (DMI)

Melbourne, 3000

Australia

SCHOLARLY PAPERS

8

DOWNLOADS

1,022

TOTAL CITATIONS

10

Scholarly Papers (8)

1.

First Report of a Phase 1 Randomised Trial of Molecular Clamp-Stabilised Spike Protein-Based and MF59-Adjuvanted Vaccine for SARS-CoV-2

Number of pages: 37 Posted: 01 Feb 2021
University of Queensland - School of Chemistry and Molecular Biosciences, University of Melbourne - Department of Microbiology and Immunology (DMI), Australian National University (ANU) - Department of Immunology and Infectious Disease, University of Queensland - School of Chemistry and Molecular Biosciences, Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, at The Peter Doherty Institute for Infection and Immunity, University of Queensland - School of Chemistry and Molecular Biosciences, University of Queensland - School of Chemistry and Molecular Biosciences, University of Queensland - School of Chemistry and Molecular Biosciences, University of Queensland - School of Chemistry and Molecular Biosciences, University of Queensland, University of Queensland - Australian Institute for Bioengineering and Nanotechnology (AIBN), Tanawell Consulting, University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Department of Microbiology and Immunology (DMI), Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, The University of Melbourne, University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Peter Doherty Institute for Infection and Immunity, University of Queensland - TetraQ, University of Queensland - TetraQ, University of Melbourne - WHO Collaborating Centre for Reference and Research on Influenza, Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, at The Peter Doherty Institute for Infection and Immunity, Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, at The Peter Doherty Institute for Infection and Immunity, Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, at The Peter Doherty Institute for Infection and Immunity, Burnet Institute, Burnet Institute, University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Department of Microbiology and Immunology (DMI), Australian National University (ANU) - Department of Immunology and Infectious Disease, University of Melbourne - WHO Collaborating Centre for Reference and Research on Influenza, University of Queensland - Institute for Molecular Bioscience, University of Queensland - School of Chemistry and Molecular Biosciences and University of Queensland - School of Chemistry and Molecular Biosciences
Downloads 414 (176,035)
Citation 2

Abstract:

Loading...

2.

Interim Results from a Phase I Trial of Novel SARS-CoV-2 Beta Variant Receptor-Binding Domain Recombinant Protein and mRNA Vaccines as a 4 th Dose Booster

Number of pages: 43 Posted: 29 Jun 2023
University of Melbourne - Peter Doherty Institute for Infection and Immunity, University of Melbourne, University of Melbourne, University of Melbourne - Departments of Medicine and Infectious Diseases at the Doherty Institute, University of Melbourne - Department of Microbiology and Immunology, University of Melbourne - Peter Doherty Institute for Infection and Immunity, University of Melbourne - Peter Doherty Institute for Infection and Immunity, University of Melbourne, University of Melbourne, University of Melbourne, Flinders University, University of Melbourne, University of Melbourne, University of Melbourne, University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Peter Doherty Institute for Infection and Immunity, University of Melbourne, University of Melbourne - Department of Microbiology and Immunology, University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne, University of Melbourne, University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne, University of Melbourne - Royal Melbourne Hospital, University of Melbourne - Centre for Epidemiology and Biostatistics, University of Melbourne, Monash University - Monash Institute of Pharmaceutical Sciences, Monash University - Monash Institute of Pharmaceutical Sciences, Monash University - Monash Institute of Pharmaceutical Sciences, SingHealth Duke-NUS Global Health Institute, University of Melbourne - Department of Microbiology and Immunology (DMI), Flinders University, Duke-NUS Medical School - Programme in Emerging Infectious Diseases, Monash University - Monash Institute of Pharmaceutical Sciences, University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Centre for Epidemiology and Biostatistics, Monash University - Monash Institute of Pharmaceutical Sciences and University of Melbourne - Department of Microbiology and Immunology (DMI)
Downloads 128 (569,079)

Abstract:

Loading...

SARS-CoV-2, vaccine, receptor binding domain, recombinant protein, mRNA, beta variant, phase I trial.

3.

The Platform Trial in COVID-19 Priming and BOOsting (PICOBOO): The Immunogenicity, Reactogenicity, and Safety of Licensed COVID-19 Vaccinations Administered as a Second Booster in BNT162b2 Primed Individuals Aged 18-<50 and 50-<70 Years Old

Number of pages: 39 Posted: 08 Jul 2024
Perth Children’s Hospital - Telethon Kids Institute, Perth Children’s Hospital - Telethon Kids Institute, University of Tasmania - School of Health Sciences and School of Medicine, Royal Melbourne Institute of Technology (RMIT University), University of Adelaide - Vaccinology and Immunology Research Trials Unit, The University of Sydney, Perth Children's Hospital - Department of Infectious Diseases, Perth Children’s Hospital - Telethon Kids Institute, Perth Children’s Hospital - Wesfarmer's Centre for Vaccines and Infectious Diseases, University of Melbourne - WHO Collaborating Centre for Reference and Research on Influenza, University of Melbourne - Department of Microbiology and Immunology (DMI), Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, at The Peter Doherty Institute for Infection and Immunity, affiliation not provided to SSRN, affiliation not provided to SSRN, University of Southampton - NIHR Southampton Clinical Research Facility and Biomedical Research Centre, Perth Children’s Hospital - Telethon Kids Institute, Perth Children’s Hospital - Telethon Kids Institute, Perth Children’s Hospital - Telethon Kids Institute, Charles Darwin University - Menzies School of Health Research and The University of Western Australia
Downloads 117 (613,149)
Citation 1

Abstract:

Loading...

COVID-19, Booster Vaccines, Immunogenicity, adaptive platform trial, health policy.

4.

The Platform Trial in COVID-19 Priming and Boosting (PICOBOO): The Immunogenicity, Reactogenicity, and Safety of Different COVID-19 Vaccinations Administered as a Second Booster (Fourth Dose) in Azd1222 Primed Individuals Aged 50-<70 Years Old

Number of pages: 13 Posted: 07 May 2024
Perth Children’s Hospital - Telethon Kids Institute, Perth Children’s Hospital - Telethon Kids Institute, University of Tasmania - School of Health Sciences and School of Medicine, Royal Melbourne Institute of Technology (RMIT University), University of Adelaide - Vaccinology and Immunology Research Trials Unit, The University of Sydney, Perth Children's Hospital - Department of Infectious Diseases, Perth Children’s Hospital - Telethon Kids Institute, Perth Children’s Hospital - Wesfarmer's Centre for Vaccines and Infectious Diseases, University of Melbourne - WHO Collaborating Centre for Reference and Research on Influenza, University of Melbourne - Department of Microbiology and Immunology (DMI), Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital, at The Peter Doherty Institute for Infection and Immunity, University of Southampton - NIHR Southampton Clinical Research Facility and Biomedical Research Centre, Perth Children’s Hospital - Telethon Kids Institute, Perth Children’s Hospital - Telethon Kids Institute, Perth Children’s Hospital - Telethon Kids Institute, Charles Darwin University - Menzies School of Health Research and The University of Western Australia
Downloads 110 (640,165)

Abstract:

Loading...

Adaptive platform trial, COVID-19, vaccines, Bayesian, immunisation, policy

5.

Long-Term Safety and Immunogenicity of an MF59-Adjuvanted Spike Glycoprotein-Clamp Vaccine for SARS-CoV-2 in Adults Aged 18–55 Years or ≥56 Years: 12-Month Results from a Randomised, Double-Blind, Placebo-Controlled, Phase 1 Trial

Number of pages: 51 Posted: 28 Mar 2023
University of Queensland - School of Chemistry and Molecular Biosciences, University of Melbourne - Department of Microbiology and Immunology (DMI), University of Queensland - School of Chemistry and Molecular Biosciences, University of Queensland - School of Chemistry and Molecular Biosciences, University of Melbourne, Australian National University (ANU) - Department of Immunology and Infectious Disease, University of Queensland - School of Chemistry and Molecular Biosciences, University of Queensland - School of Chemistry and Molecular Biosciences, University of Queensland - School of Medicine, Tanawell Consulting, University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Department of Microbiology and Immunology (DMI), Agilex Biolabs, Agilex Biolabs, University of Melbourne - WHO Collaborating Centre for Reference and Research on Influenza, University of Melbourne - WHO Collaborating Centre for Reference and Research on Influenza, University of Melbourne - Department of Microbiology and Immunology (DMI), Australian National University (ANU) - Department of Immunology and Infectious Disease, University of Melbourne - WHO Collaborating Centre for Reference and Research on Influenza, University of Queensland - Institute for Molecular Bioscience, University of Queensland - School of Chemistry and Molecular Biosciences and University of Queensland - School of Chemistry and Molecular Biosciences
Downloads 78 (816,709)

Abstract:

Loading...

Clinical trial, phase 1, COVID-19 vaccine, Severe acute respiratory syndrome coronavirus 2, Spike protein, SARS-CoV-2, Molecular clamp

6.

Re: Integrated Immune Dynamics Define Correlates of COVID-19 Severity and Antibody Responses

Number of pages: 56 Posted: 13 Oct 2020
University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Department of Microbiology and Immunology (DMI), The University of Sydney - Sydney Cytometry Core Research Facility, The University of Sydney - Charles Perkins Centre, The University of Sydney - Charles Perkins Centre, The University of Sydney - School of Computer Science, The University of Sydney - School of Computer Science, University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Department of Microbiology and Immunology (DMI), Icahn School of Medicine at Mount Sinai - Department of Microbiology, University of Melbourne - Peter Doherty Institute for Infection and Immunity, The Austin Hospital - Department of Infectious Diseases, Monash Medical Centre - Monash Infectious Diseases, Peter Doherty Institute for Infection and Immunity - Victorian Infectious Diseases Reference Laboratory, University of Melbourne - Peter Doherty Institute for Infection and Immunity, University of Melbourne - Peter Doherty Institute for Infection and Immunity, QIMR Berghofer Medical Research Institute - Infectious Diseases Programme, Monash University - Respiratory Medicine Laboratory, University of Melbourne - Department of Microbiology and Immunology (DMI), Icahn School of Medicine at Mount Sinai - Department of Microbiology, University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Peter Doherty Institute for Infection and Immunity, The University of Sydney - Sydney Cytometry Core Research Facility, University of Melbourne - Peter Doherty Institute for Infection and Immunity, University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - WHO Collaborating Centre for Reference and Research on Influenza, Monash University - Department of Infectious Diseases, University of Melbourne - Peter Doherty Institute for Infection and Immunity, University of Melbourne - Department of Microbiology and Immunology (DMI), Monash University - Department of Infectious Diseases and University of Melbourne - Department of Microbiology and Immunology (DMI)
Downloads 60 (961,006)
Citation 5

Abstract:

Loading...

COVID-19, immune correlates, disease severity, IL-6R, hyperactivation

7.

High Precursor Frequency and Promiscuity in Αβ T Cell Receptor Pairing Underpin CD8+ T-Cell Responses to an Immunodominant SARS-CoV-2 Nucleocapsid Epitope

Number of pages: 35 Posted: 19 Dec 2020
University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Department of Microbiology and Immunology (DMI), Monash University - Infection and Immunity Program, University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Department of Microbiology and Immunology (DMI), Monash University - Infection and Immunity Program, University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Department of Microbiology and Immunology (DMI), Icahn School of Medicine at Mount Sinai - Department of Microbiology, Icahn School of Medicine at Mount Sinai - Department of Microbiology, James Cook University - Centre for Molecular Therapeutics, Icahn School of Medicine at Mount Sinai - Department of Microbiology, University of Tasmania - School of Medicine, University of Tasmania - School of Medicine, University of Melbourne - Department of Microbiology and Immunology (DMI), Alfred Hospital - Lung Transplant Unit, Austin Hospital - Department of Infectious Diseases, Austin Hospital - Department of Infectious Diseases, University of Melbourne - Department of Microbiology and Immunology (DMI), The Austin Hospital - Department of Infectious Diseases, Austin Hospital - Department of Infectious Diseases, Monash University - Department of Infectious Diseases, Monash University - Department of Infectious Diseases, AFL House, University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Department of Microbiology and Immunology (DMI), Monash University - Infection and Immunity Program, University of Melbourne - Department of Microbiology and Immunology (DMI) and University of Melbourne - Department of Microbiology and Immunology (DMI)
Downloads 58 (980,173)

Abstract:

Loading...

8.

Rapid Application of the Molecular Clamp Platform for SARS-CoV-2

Number of pages: 65 Posted: 24 Nov 2020
University of Queensland - Institute for Molecular Bioscience, University of Queensland - School of Chemistry and Molecular Biosciences, University of Queensland - School of Chemistry and Molecular Biosciences, University of Melbourne - Department of Microbiology and Immunology (DMI), Australian National University (ANU) - Department of Immunology and Infectious Disease, University of Queensland - School of Chemistry and Molecular Biosciences, University of Queensland - School of Chemistry and Molecular Biosciences, University of Queensland - School of Chemistry and Molecular Biosciences, Viroclinics Xplore, Viroclinics Xplore, Viroclinics Xplore, University of Queensland - School of Chemistry and Molecular Biosciences, University of Queensland - School of Chemistry and Molecular Biosciences, University of Queensland - Australian Institute for Bioengineering and Nanotechnology (AIBN), University of Queensland - Australian Institute for Bioengineering and Nanotechnology (AIBN), University of Queensland - Australian Institute for Bioengineering and Nanotechnology (AIBN), University of Queensland - Australian Institute for Bioengineering and Nanotechnology (AIBN), University of Queensland - Australian Institute for Bioengineering and Nanotechnology (AIBN), University of Queensland - Australian Institute for Bioengineering and Nanotechnology (AIBN), University of Queensland - Australian Institute for Bioengineering and Nanotechnology (AIBN), University of Queensland - Australian Institute for Bioengineering and Nanotechnology (AIBN), University of Queensland - Australian Institute for Bioengineering and Nanotechnology (AIBN), CSIRO Manufacturing, CSIRO Manufacturing, CSIRO Manufacturing, CSIRO Manufacturing, CSIRO Manufacturing, CSIRO Manufacturing, CSIRO Manufacturing, CSIRO Manufacturing, University of Queensland - TetraQ, StageBio, University of Queensland - Centre for Advanced Materials Processing and Manufacturing, University of Queensland - TetraQ, University of Queensland - TetraQ, University of Melbourne - Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity - WHO Collaborating Centre for Reference and Research on Influenza, University of Queensland - School of Chemistry and Molecular Biosciences, University of Queensland - School of Chemistry and Molecular Biosciences, University of Queensland - School of Chemistry and Molecular Biosciences, University of Queensland - School of Chemistry and Molecular Biosciences, University of Queensland - School of Chemistry and Molecular Biosciences, University of Queensland - Australian Infectious Diseases Research Centre, Utrecht University - Division of Pathology, University of Melbourne - WHO Collaborating Centre for Reference and Research on Influenza, Australian National University (ANU) - Department of Immunology and Infectious Disease, University of Melbourne - WHO Collaborating Centre for Reference and Research on Influenza, University of Queensland - School of Chemistry and Molecular Biosciences, University of Queensland - School of Chemistry and Molecular Biosciences and University of Queensland - School of Chemistry and Molecular Biosciences
Downloads 57 (989,921)
Citation 2

Abstract:

Loading...

SARS-CoV-2, Molecular Clamp, subunit vaccine, rapid response, hamster protection, neutralising antibodies, polyfunctional T cells, cytotoxic CD8+ T cells, helper T cells, immune breadth